Neutralization of ARCoV-induced sera against SARS-CoV-2 variants

ARCoV is a candidate mRNA vaccine encoding receptor-binding domain of SARS-CoV-2. Its safety, tolerability, and immunogenicity profile have been confirmed in the phase 1 clinical trial in China. A multi-regional phase 3 clinical trial is currently underway to test the efficacy of ARCoV (NCT04847102)...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiao-Feng, Zhang, Na-Na, Li, Yu-Hua, Cao, Shou-Chun, Zhang, Yi-Fei, Qin, Cheng-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronavirus – Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746371/
https://www.ncbi.nlm.nih.gov/pubmed/35816411
http://dx.doi.org/10.1080/21645515.2022.2094142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746371/
https://www.ncbi.nlm.nih.gov/pubmed/35816411
http://dx.doi.org/10.1080/21645515.2022.2094142

Ejemplares similares